Swiss National Bank Trims Stake in AbbVie Inc. $ABBV

Swiss National Bank lessened its holdings in AbbVie Inc. (NYSE:ABBV) by 4.9% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,091,810 shares of the company’s stock after selling 263,000 shares during the period. AbbVie accounts for approximately 0.7% of Swiss National Bank’s portfolio, making the stock its 21st largest holding. Swiss National Bank owned approximately 0.29% of AbbVie worth $1,178,958,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Evolution Wealth Management Inc. purchased a new stake in shares of AbbVie in the 2nd quarter valued at about $26,000. Caitlin John LLC bought a new stake in shares of AbbVie during the 3rd quarter valued at about $33,000. Financial Gravity Companies Inc. purchased a new position in shares of AbbVie during the second quarter worth about $36,000. Delos Wealth Advisors LLC bought a new position in shares of AbbVie in the second quarter worth approximately $39,000. Finally, Redmont Wealth Advisors LLC bought a new position in shares of AbbVie in the third quarter worth approximately $41,000. Institutional investors own 70.23% of the company’s stock.

AbbVie Price Performance

Shares of NYSE ABBV opened at $230.41 on Monday. The stock has a market capitalization of $407.40 billion, a P/E ratio of 97.63, a PEG ratio of 0.80 and a beta of 0.34. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81. The firm’s 50 day simple moving average is $224.72 and its two-hundred day simple moving average is $224.21.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. During the same period in the previous year, the business posted $2.16 EPS. The business’s quarterly revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, equities analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.0%. The ex-dividend date is Wednesday, April 15th. AbbVie’s dividend payout ratio is presently 293.22%.

Insider Activity

In other news, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. The trade was a 66.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares of the company’s stock, valued at $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 0.08% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and lifted their target price for the company from $225.00 to $265.00 in a research report on Wednesday, December 10th. Evercore lowered their price objective on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 4th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $223.00 price objective on shares of AbbVie in a report on Wednesday, January 28th. Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. Finally, Piper Sandler increased their target price on AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $253.15.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.